文献速递肝病

非选择性β受体阻滞剂对失代偿期肝硬化急性肾损伤结局的影响

Impact of non-selective beta-blockers on acute kidney injury outcomes in patients with decompensated cirrhosis.
PubMed 文献 · J Hepatol · 2026-07-15

这项多中心研究纳入1238例因失代偿期肝硬化合并急性肾损伤(AKI)住院的患者,评估非选择性β受体阻滞剂(NSBB)对AKI结局的影响。经逆概率治疗加权调整后,AKI诊断时使用NSBB与更高的AKI缓解率和更低的28天死亡率相关;住院期间继续使用NSBB未见有害证据,支持个体化管理而非一律停药。

要点

  • AKI诊断时使用NSBB与更高的AKI缓解率相关(sHR 1.29)。
  • AKI诊断时使用NSBB与更低的28天死亡率相关(sHR 0.70)。
  • 住院期间继续使用NSBB未见与AKI缓解或28天死亡率的有害关联。

核心结论

  • AKI诊断时使用NSBB与失代偿期肝硬化合并AKI患者肾脏恢复改善和生存改善相关。
  • 住院期间继续使用NSBB未见有害,支持谨慎的个体化管理而非系统性停药。

研究设计与样本

  • 多中心研究,纳入因失代偿期肝硬化合并AKI住院的患者共1238例。
  • 收集NSBB治疗类型、剂量及继续、停用或减量情况,采用逆概率治疗加权(IPTW)平衡混杂因素。
  • 主要结局为AKI缓解和28天死亡率。

主要发现

  • 1238例AKI患者中503例使用NSBB(普萘洛尔55%,卡维地洛45%)。
  • IPTW调整后,AKI诊断时使用NSBB与更高的AKI缓解率相关(sHR 1.29;95%CI 1.12-1.48;p<0.001)。
  • IPTW调整后,AKI诊断时使用NSBB与更低的28天死亡率相关(sHR 0.70;95%CI 0.55-0.91;p=0.006)。
  • AKI诊断后48-72小时,122例(24%)继续使用NSBB,349例(69%)停用或减量;4例死亡,28例数据不可用。
  • 排除59例临床不可继续使用NSBB者后,IPTW调整分析未发现继续使用NSBB与AKI缓解(sHR 0.84;95%CI 0.57-1.25;p=0.391)或28天死亡率(sHR 0.51;95%CI 0.23-1.11;p=0.089)存在关联的证据。

临床怎么用

  • 失代偿期肝硬化合并AKI患者不应仅因AKI而系统性停用NSBB,应结合血流动力学等个体化评估。
  • 住院期间继续使用NSBB未见有害,可谨慎继续使用并密切监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Non-selective beta-blockers (NSBBs) are widely used to prevent decompensation in cirrhosis. Guidelines recommend discontinuing NSBBs in patients with cirrhosis and acute kidney injury (AKI), although this recommendation is based largely on expert opinion and limited evidence. We evaluated the impact of NSBB use on AKI outcomes in patients with cirrhosis. METHODS: This multicenter study enrolled patients hospitalized for decompensated cirrhosis and AKI. Data on NSBB treatment, including type, dose, and continuation, discontinuation, or tapering, were collected. Outcomes were compared between patients receiving and not receiving NSBBs and between those who discontinued/tapered and those who did not. Inverse probability of treatment weighting (IPTW) was used to balance demographics, liver disease severity, hemodynamic parameters, AKI stage and acute-on-chronic liver failure (ACLF) grade. The main outcomes were AKI resolution and 28-day mortality. RESULTS: Of 1,238 patients with AKI, 503 were on NSBBs (propranolol 55%; carvedilol 45%). After IPTW adjustment, NSBB treatment at AKI diagnosis was associated with higher likelihood of AKI resolution (subdistribution hazard ratio [sHR] 1.29; 95% CI 1.12-1.48; p <0.001) and reduced 28-day mortality (sHR 0.70; 95% CI 0.55-0.91; p = 0.006). At 48-72 hours from AKI diagnosis, NSBBs were continued in 122 patients (24%) and discontinued/tapered in 349 (69%); 4 patients died, and data were not available for the remaining 28 patients. After excluding patients in whom NSBB continuation was not clinically feasible (n = 59), IPTW-adjusted analysis showed no evidence of an association between NSBB continuation and AKI resolution (sHR 0.84; 95% CI 0.57-1.25; p = 0.391) or 28-day mortality (sHR 0.51; 95% CI 0.23-1.11; p = 0.089). CONCLUSION: NSBB use at AKI diagnosis was associated with improved renal recovery and survival in patients with acutely decompensated cirrhosis and AKI. Continuation during hospitalization does not appear harmful, supporting careful individualized management rather than systematic withdrawal. IMPACT AND IMPLICATIONS: Owing to potential adverse hemodynamic effects, current guidelines recommend discontinuation of non-selective beta-blockers (NSBBs) in patients with acute decompensation (AD) of cirrhosis and acute kidney injury (AKI). However, this recommendation relies largely on expert opinion, since robust clinical evidence is lacking. This study prospectively evaluated the impact of NSBBs on AKI outcomes in a large multicentre cohort of patients with AD and AKI. Treatment with NSBBs at AKI diagnosis was associated with greater likelihood of AKI resolution and lower risk of 28-day mortality, while no evidence of an association between early discontinuation and improved outcomes was observed. These findings support a personalized approach to NSBB management in decompensated patients with AKI and highlight the need to identify patients who may benefit most from NSBB discontinuation.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Incicco S, Patidar KR, Juanola A, et al. Impact of non-selective beta-blockers on acute kidney injury outcomes in patients with decompensated cirrhosis. J Hepatol. 2026. PMID: 42457041. doi:10.1016/j.jhep.2026.06.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。